Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome

07-Jan-2013 - The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Neupro® (rotigotine transdermal patch) for the treatment of Parkinson’s disease (PD) and for the symptomatic treatment of moderate-to-severe idiopathic Restless Legs Syndrome (RLS) in adults. In 2002 Otsuka Pharmaceutical ...

Otsuka Pharmaceutical and UCB focus collaboration in the area of Central Nervous System (CNS) disorders

16-Jan-2012 - Otsuka Pharmaceutical Co., Ltd. and UCB announced that the companies have agreed to focus their collaboration on the therapeutic area of Central Nervous System (CNS) disorders and to discontinue their collaboration in immunology. The companies will end their co-development and co-promotion ...

E Keppra (levetiracetam) receives regulatory approval in Japan

Otsuka Pharmaceutical and UCB Japan to co-promote E Keppra

26-Jul-2010 - Otsuka Pharmaceutical Co., Ltd. and UCB announced that UCB Japan has received manufacturing and marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Keppra® (250 mg and 500 mg Tablets). E Keppra® has been approved in Japan as adjunctive therapy in the treatment ...

European Commission approves Samsca for Hyponatraemia

04-Aug-2009 - Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced that the European Commission has approved the Marketing Authorisation Application for the company’s oral once-daily medication Samsca™(tolvaptan), a selective V2-vasopressin receptor antagonist, for the ...

American Peptide Company to be Acquired by Otsuka Chemical Company

Acquisition Offers American Peptide Company Access to Greater Resources

01-Aug-2008 - American Peptide Company, Inc. announced that its parent company, Ito Life Sciences (Ibaraki, Japan), will be acquired by Otsuka Chemical Company (Osaka, Japan), part of the Otsuka Group (Osaka, Japan). Otsuka Chemical Company will be the new owner of American Peptide Company and Ito Life ...

GW and Otsuka Pharmaceutical Enter Into Global Cannabinoid Research Collaboration

12-Jul-2007 - GW Pharmaceuticals and Otsuka Pharmaceutical Co., Ltd. have signed a global cannabinoid research collaboration in the field of Central Nervous System (CNS) and oncology in order to research, develop and commercialize a range of candidate cannabinoid products. The cannabinoid research ...